Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Intra-Arterial Albumin as Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke: A Multicenter, Prospective, Open-Label, Endpoint-Blinded, Randomized Controlled Clinical Trial (AMASS2)

NCT07365475 is registered in ClinicalTrials.gov with Tianjin Huanhu Hospital as lead sponsor.

NCT NCT07365475
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07365475 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Intra-Arterial Albumin as Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke: A Multicenter, Prospective, Open-Label, Endpoint-Blinded, Randomized Controlled Clinical Trial (AMASS2)
Lead sponsor
Tianjin Huanhu Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
January 30, 2026
Completion date
August 30, 2028
Enrollment
306 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke from large vessel occlusion